<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Management - adults | Management | Polycystic ovary syndrome | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the management of polycystic ovary syndrome (PCOS) and associated disorders in adults."/><meta data-react-helmet="true" property="og:description" content="Covers the management of polycystic ovary syndrome (PCOS) and associated disorders in adults."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/polycystic-ovary-syndrome/management/management-adults/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Management - adults | Management | Polycystic ovary syndrome | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/polycystic-ovary-syndrome/management/management-adults/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Polycystic ovary syndrome</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Management - adults</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/polycystic-ovary-syndrome/","name":"Polycystic ovary syndrome"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/polycystic-ovary-syndrome/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Management - adults"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Polycystic ovary syndrome: </span><span>Scenario: Management of polycystic ovary syndrome in adults</span></h1><p class="page-header__lead"><span>Last revised in September2018</span></p></div><p class="visually-hidden">Covers the management of polycystic ovary syndrome (PCOS) and associated disorders in adults.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Polycystic ovary syndrome chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management - adults"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Management - adults</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management - adolescents"><a aria-current="false" href="../management-adolescents/index.html"><span class="stacked-nav__content-wrapper">Scenario: Management - adolescents</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#general-management">General management</a><ol aria-label="Sections within General management" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-498">Basis for recommendation</a></li></ol></li><li><a href="index.html#screening-for-type-2-diabetes-insulin-resistance">Screening for type 2 diabetes and insulin resistance</a><ol aria-label="Sections within Screening for type 2 diabetes and insulin resistance" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-3e2">Basis for recommendation</a></li></ol></li><li><a href="index.html#screening-for-cardiovascular-risk-factors">Screening for cardiovascular risk factors</a><ol aria-label="Sections within Screening for cardiovascular risk factors" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-d22">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-clinical-features-of-polycystic-ovary-syndrome">Managing clinical features of polycystic ovary syndrome</a><ol aria-label="Sections within Managing clinical features of polycystic ovary syndrome" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-7db">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="management-adults" class="ChapterBody-module--wrapper--2HCfk "><h2 id="management-adults" class="visually-hidden">Scenario: Management of polycystic ovary syndrome in adults</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 50c6c341-4985-4028-a7e7-4c5fadb0ee62 --><!-- begin field 6eaf6f4c-0a15-446d-a816-acbc0157fd6a --><p>From age 18 years onwards (Female).</p><!-- end field 6eaf6f4c-0a15-446d-a816-acbc0157fd6a --><!-- end item 50c6c341-4985-4028-a7e7-4c5fadb0ee62 --></div><section aria-labelledby="general-management" class="ChapterBody-module--wrapper--2HCfk "><h3 id="general-management">How should I manage polycystic ovary syndrome in adults?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6060b4e3-7607-423f-9063-30082a88a0a9 --><!-- begin field ef000e9e-a3fb-4920-ad46-21036045e2e5 --><ul><li><strong>Inform women diagnosed withpolycystic ovary syndrome (PCOS) about the possible long-term <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a> of PCOS,</strong> including type2 diabetes and cardiovascular disease (CVD).<ul><li>Encourage a healthy lifestyle to reduce the risk of these complications and to help improve the clinical featuresof PCOS, including oligomenorrhoea or amenorrhoea, acne, hirsutism, and infertility.</li><li>For women who are overweight or obese,offer adviceon weight loss or consider referral to a dietitian. See the CKS topic on<a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li><li>Explain that weight loss may:<ul><li>Reduce hyperinsulinism and hyperandrogenism.</li><li>Reduce the risk of type2 diabetes and CVD.</li><li>Result in menstrual regularity.</li><li>Improve the chance of pregnancy (if it is desired).</li></ul></li></ul></li><li><strong>Offer screening for:</strong><ul><li>Impaired glucose tolerance and type 2 diabetes. See the section on<a class="topic-reference internal-reference" href="index.html#screening-for-type-2-diabetes-insulin-resistance">Screening for type 2 diabetes and insulin resistance</a> for more information.</li><li>Cardiovascular risk factors. See the section on<a class="topic-reference internal-reference" href="index.html#screening-for-cardiovascular-risk-factors">Screening for cardiovascular risk factors</a>for more information.</li></ul></li><li><strong>Ask about snoring and daytime fatigue/somnolence.</strong><ul><li>If there are symptoms of obstructive sleep apnoea, refer for investigation and treatment.</li><li>See the CKS topic on<a class="topic-reference external-reference" href="../../../obstructive-sleep-apnoea-syndrome/index.html">Obstructive sleep apnoea syndrome</a>for more information.</li></ul></li><li><strong>Ask about emotional well being, and manage as appropriate.</strong><ul><li>Screen for depression and anxiety, where appropriate.See the CKS topicson<a class="topic-reference external-reference" href="../../../depression/index.html">Depression</a>and<a class="topic-reference external-reference" href="../../../generalized-anxiety-disorder/index.html">Generalized anxiety disorder</a>for more information.</li><li>Consider the possibility of the following:<ul><li>Psychosexual problemshirsutism, obesity, oligomenorrhoea, and infertility may lead to feelings of being unattractive, and loss of feminine identity.</li><li>Negative body image women with PCOS may feel less physically attractive, physically fit or healthy and may be less satisfied with their body size than women without PCOS.</li><li>Eating disorders  these includeanorexia nervosa,bulimia nervosa, binge-eating disorder,and atypical eating disorders. See the CKS topic<a class="topic-reference external-reference" href="../../../eating-disorders/index.html">Eating disorders</a>.</li></ul></li></ul></li><li><strong>Manage<strong>the clinical features</strong><strong>of PCOS</strong>, including </strong>oligomenorrhoea or amenorrhoea, acne, hirsutism, and infertility.See the section on<a class="topic-reference internal-reference" href="index.html#managing-clinical-features-of-polycystic-ovary-syndrome">Managing clinical features of polycystic ovary syndrome</a> for more information.</li><li><strong>For women with PCOS who are pregnant or considering pregnancy:</strong><ul><li>Consider referring the woman to be screened for gestational diabetes.<ul><li>All women who are planning a pregnancy should be offered a 75-g oral glucose tolerance test (OGTT). If this is not performed preconception, it should be offered before 20 weeks gestation.</li><li>All pregnant women with PCOS should be offered an OGTT at 2428 weeks gestation.</li></ul></li><li>Consider whether any changes to drug treatment(s) should be made. For example,<ul><li>Metformin is not recommended in pregnancy. Seek specialist advice.</li><li>Any hormonal treatment (such as medroxyprogesterone for inducing cyclical bleeding) should be stopped.</li></ul></li></ul></li><li><strong>Provide sources of additional information and support. </strong>For example:<ul><li>Information on PCOS are available from:<ul><li>TheRoyal College of Obstetricians and Gynaecologists (RCOG) website (www.rcog.org.uk): <a data-hyperlink-id="4c54ce56-014b-4b6f-854f-a95f00cb5582" href="https://www.rcog.org.uk/globalassets/documents/patients/patient-information-leaflets/gynaecology/pi-pcos.pdf">Polycystic ovary syndrome: what it means for your long-term health</a>.</li><li>NHS (www.nhs.uk): <a data-hyperlink-id="4c363da2-b2bd-4693-abdc-a95f00cb55d8" href="https://www.nhs.uk/conditions/polycystic-ovary-syndrome-pcos/">Polycystic ovary syndrome</a>.</li></ul></li><li>Support groups for people with PCOS include:<ul><li>PCOS Challenge: The National Polycystic Ovary Syndrome Association(<a data-hyperlink-id="52cac0f3-2b9d-42d9-9b67-a96700c58c1f" href="https://www.pcoschallenge.org/about-pcos-challenge/">www.pcoschallenge.org</a>).</li><li>Verity (<a data-hyperlink-id="e7448387-1932-4df7-ab2c-a96700c58c95" href="https://www.verity-pcos.org.uk/about-us.html">www.verity-pcos.org.uk</a>).</li></ul></li></ul></li></ul><!-- end field ef000e9e-a3fb-4920-ad46-21036045e2e5 --><!-- end item 6060b4e3-7607-423f-9063-30082a88a0a9 --></div><section aria-labelledby="basis-for-recommendation-498" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-498">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 498cb71c-edc0-4127-a0e6-a95e00e075ea --><!-- begin field cd638223-546b-46cb-b86b-a95e00e0761f --><p>These recommendations are based largely on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Long-term Consequences of Polycystic Ovary Syndrome</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>],<em>The polycystic ovary syndrome: a position statement from the European Society of Endocrinology </em>(ESE) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Conway, 2014</a>], and the<em>I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued bythe International Polycystic Ovary Syndrome (PCOS) Network [<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</p><h5>Encouraging a healthy lifestyle</h5><ul><li>The ESE advises that [<a class="bibliography-reference internal-reference" href="../../references/index.html">Conway, 2014</a>]:<ul><li>Lifestyle modification, including diet and exercise, should be the first-line treatment in overweight and obese women with PCOS.</li><li>Regular exercisecombined with dietary advice aiming at sustained weight loss may ameliorate many aspects of PCOS in overweight/obese women.<ul><li>For example, weight reduction alone may result in spontaneous ovulation in these women, and in women who do not ovulate spontaneously following weight reduction and lifestyle modifications, the response to induction of ovulation is likely to be improved by these measures.</li></ul></li></ul></li><li>The International PCOS Network advises that[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>]:<ul><li>Healthy lifestyle behaviours (including healthy eating and regular physical activity) should be recommended in all those with PCOS to achieve and/or maintain a healthy weight and to optimize hormonal outcomes, general health, and quality of life.</li><li>Lifestyle intervention (preferably multicomponent, including diet, exercise, and behavioural strategies) should be recommended in all those with PCOS and excess weight, for reductions in weight, central obesity, and insulin resistance.</li></ul></li><li>Expert opinion in a British Fertility SocietyPolicy and Practice Guidelines is thata loss of more than 5% in body weight can be enough to restore fertility and improve metabolic markers[<a class="bibliography-reference internal-reference" href="../../references/index.html">Balen and Anderson, 2007</a>].</li></ul><h5>Offering screening for impaired glucose tolerance and type 2 diabetes</h5><ul><li>See the section on<a class="topic-reference internal-reference" href="index.html#screening-for-type-2-diabetes-insulin-resistance">Screening for type 2 diabetes and insulin resistance</a> for more information.</li></ul><h5>Offering screening for cardiovascular risk factors</h5><ul><li>See the section on<a class="topic-reference internal-reference" href="index.html#screening-for-cardiovascular-risk-factors">Screening for cardiovascular risk factors</a>for more information.</li></ul><h5>Asking about snoring and daytime fatigue/somnolence</h5><ul><li>The prevalence of obstructive sleep apnoea is increased in obese women with PCOS. See the section on<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">Complications</a> for more information.</li><li>The International PCOS Network advises that screening for obstructive sleep apnoea should be considered to identify and alleviate related symptoms, such as snoring, waking unrefreshed from sleep, daytime sleepiness, and the potential for fatigue to contribute to mood disorders[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</li></ul><h5>Asking about emotional well being</h5><ul><li>Women with PCOS are atincreased risk of psychological and behavioural disorders as well as reduced quality of life.See the section on<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">Complications</a> for more information.</li><li>The International PCOS Network advises that health professionals should be aware of the increased prevalence of psychosexual dysfunction and should consider exploring how features of PCOS, including hirsutism and body image, impact on sex life and relationships in PCOS[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</li></ul><h5>Managing the clinical features of PCOS</h5><ul><li><p>See the section on<a class="topic-reference internal-reference" href="index.html#managing-clinical-features-of-polycystic-ovary-syndrome">Managing clinical features of polycystic ovary syndrome</a> for more information.</p></li></ul><h5>Managing women with PCOS who are pregnant or considering pregnancy</h5><ul><li>Women with PCOS have a clinically significant increased risk of pregnancy complications compared with women without PCOS. See the section on<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">Complications</a> for more information.</li><li>The information on when and how an oral glucose tolerance test should be done is based on expert opinion in the RCOG guideline[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>] and the <em>International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</li><li>The recommendation to considerwhether any changes to drug treatment should be made is based on what CKS considers to be good clinical practice.</li></ul><h5>Providing sources of additional information and support</h5><ul><li>Providingsources of additional information and support is based on expert opinion inthe<em>International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</li></ul><!-- end field cd638223-546b-46cb-b86b-a95e00e0761f --><!-- end item 498cb71c-edc0-4127-a0e6-a95e00e075ea --></div></section></section><section aria-labelledby="screening-for-type-2-diabetes-insulin-resistance" class="ChapterBody-module--wrapper--2HCfk "><h3 id="screening-for-type-2-diabetes-insulin-resistance">How should I screen for type 2 diabetes and insulin resistance?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 78b8747d-dcbd-4fe9-aa9e-f2acc1db101b --><!-- begin field e8b7970a-91f1-41da-bb4f-b765410fe191 --><ul><li><strong>Offer a</strong><strong>2-hour post 75 g oral glucose tolerance test (OGTT) to womenwith polycystic ovary syndrome (PCOS) who are:</strong><ul><li>Overweight (body mass index [BMI]25 kg/m<sup>2</sup> or more).</li><li>Not overweight (BMI less than25 kg/m<sup>2</sup> ) but have additional risk factors, such as advanced age (older than40 years of age), personal history of gestational diabetes, or family history of type 2diabetes.</li><li>Of non-Caucasian ethnicity (particularly south Asian women) regardless of their BMI, because of their propensity towards higher insulin resistance.</li></ul></li><li><strong>Offer an annual OGTT to women with:</strong><ul><li>Impaired fasting glucose (fasting plasma glucose level from 6.1 mmol/l to 6.9 mmol/l), <em>or</em></li><li>Impaired glucose tolerance (plasma glucose of 7.8 mmol/l or more but less than 11.1 mmol/l after a 2-hour OGTT).</li></ul></li><li><strong>Do not initiate treatment with insulin-sensitizing drugs, such as metformin, in primary care.</strong>Refer to a specialist if this is being considered.<ul><li>There is no consensus on who should be referred for consideration of insulin-sensitizing drugs. Consider referring women with:<ul><li>Severe oligomenorrhoea or amenorrhoea.</li><li>Impaired glucose tolerance or impaired fasting glucose.</li><li>Low sex hormone-binding globulin levels (as this is a surrogate marker for insulin resistance).</li></ul></li></ul></li><li>See the CKS topic on<a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a>for information on how to manage type 2 diabetes.</li></ul><!-- end field e8b7970a-91f1-41da-bb4f-b765410fe191 --><!-- end item 78b8747d-dcbd-4fe9-aa9e-f2acc1db101b --></div><section aria-labelledby="basis-for-recommendation-3e2" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-3e2">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3e2b6f56-7f06-455f-bcfc-dcfe16eb2b25 --><!-- begin field f97874c0-5528-4dd9-b8f4-c2197e1a26a6 --><p>These recommendations are based on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Long-term Consequences of Polycystic Ovary Syndrome</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>],<em>Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Wild et al, 2010</a>],<em>The polycystic ovary syndrome: a position statement from the European Society of Endocrinology </em>(ESE) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Conway, 2014</a>], and the<em>I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued bythe International PCOS Network [<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</p><h5>Offering an oral glucose tolerance test (OGTT)</h5><ul><li>Women withPCOS have an increased risk of impaired glucose tolerance and type2 diabetes. See the section on<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">Complications</a> for more information.<ul><li>The International PCOS Network advises that glycaemic status should be assessed at baseline in all women with PCOS. Thereafter, assessment should be every 13 years, depending on the presence of other diabetes risk factors[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</li><li>The RCOG advises that an annual OGTT should be performed in women with impaired fasting glucose (fasting plasma glucose level from 6.1 mmol/l to 6.9 mmol/l) or impaired glucose tolerance (plasma glucose of 7.8 mmol/l or more but less than 11.1 mmol/l after a 2-hour OGTT)[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>]</li><li>The AE-PCOSSociety advises thatan OGTT should be performed inall obese women with PCOS, in lean PCOS women with advanced age (older than 40 years), and in the presence of a personal history of gestational diabetes or a family history of type 2diabetes[<a class="bibliography-reference internal-reference" href="../../references/index.html">Wild et al, 2010</a>].</li></ul></li><li>An OGTT is considered to be appropriate for screening women with PCOS for diabetes.<ul><li>According to the RCOG, fasting blood glucose level alone has been shown to be inaccurate and results in underdiagnosis of type 2diabetes in women with PCOS, and theuse of HbA1c for the diagnosis of diabetes in PCOS needs better definition. However,if the woman is unwilling to have an OGTT or where the resources are not readily available,it would be reasonable to carry out HbA1c measurements[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>].</li><li>The ESE guideline states that fasting plasma glucose and HbA1c are not sensitive methods of screening for type 2diabetes in situations of risk, such as PCOS, although as a screening tool with adjusted criteria, fasting glucose may have some use[<a class="bibliography-reference internal-reference" href="../../references/index.html">Conway, 2014</a>].</li><li>The International PCOS Network recommends that an OGTT, fasting plasma glucose, or HbA1c may be performed to assess glycaemic status. However, in high-risk women with PCOS (including a women with a body mass index [BMI] greater than 25 kg/m<sup>2</sup> or in Asians greater than23 kg/m<sup>2</sup> , history of impaired fasting glucose, impaired glucose tolerance or gestational diabetes, family history of type 2 diabetes, hypertension, or high-risk ethnicity), an OGTT is recommended[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</li></ul></li></ul><h5>Insulin-sensitizing drugs</h5><ul><li>The RCOG makes the following points about the use of insulin-sensitizing drugs, such as metformin and the thiazolidinediones, in women with PCOS[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>]:<ul><li>There is no evidence of long-term benefit.</li><li>Evidence suggests that metformin may have short-term effects on insulin resistance in women without diabetes.</li><li>Metformin may reduce androgen levels by about 11% in women with PCOS compared with placebo.</li><li>Evidence regarding metformin and reduction in body weight is conflicting.</li><li>Women with a BMI greater than 37kg/m<sup>2</sup>may not respond well to the standard dose of metformin.</li><li>There is no current robust evidence to support the use of these drugs for the prevention of cardiovascular disease in PCOS.</li><li>Evidence suggests that metformin is no better than diet and lifestyle at improving metabolic risk and progression to type2 diabetes.</li><li>Metformin and the thiazolidinediones are unlicensed for use in PCOS.</li></ul></li><li>Due to the uncertainty about the benefits and safety of insulin-sensitizing drugs in PCOS, CKS recommends that they be initiated by a specialist.</li><li>There is no expert consensus on which women should be referred for treatment with an insulin-sensitizing drug.<ul><li>The RCOG recommends that metformin can be considered in women with PCOS who are already undergoing lifestyle treatment and do not have improvement in impaired glucose tolerance and in women with impaired glucose tolerance.</li><li>Previous expert reviewers of this CKS topic recommend referring women with:<ul><li>Severe oligomenorrhoea or amenorrhoea.</li><li>Impaired glucose tolerance or impaired fasting glucose.</li><li>Low sex hormone-binding globulin levels (as this is a surrogate marker for insulin resistance).</li></ul></li></ul></li></ul><!-- end field f97874c0-5528-4dd9-b8f4-c2197e1a26a6 --><!-- end item 3e2b6f56-7f06-455f-bcfc-dcfe16eb2b25 --></div></section></section><section aria-labelledby="screening-for-cardiovascular-risk-factors" class="ChapterBody-module--wrapper--2HCfk "><h3 id="screening-for-cardiovascular-risk-factors">How should I assess for cardiovascular risk factors?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a6ad3721-6ec7-4d68-975d-d3e1e5d62139 --><!-- begin field 5e3785f6-fe1c-4a5b-a812-6397a6f917fc --><ul><li><strong>Assess individual cardiovascular disease (CVD) risk factors,</strong>includingwaist circumference, body mass index (BMI), level of physical activity, cigarette smoking, lipid levels, blood pressure, impaired glucose tolerance, and type 2diabetes (personal and family history).<ul><li>Advise on measures to reduce cardiovascular risk,including diet, exercise, and where appropriate, weight loss and smoking cessation. See the CKS topics on<a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a>and<a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a>for more information.</li><li>Check blood pressure, and manage women with hypertension. See the CKS topicon<a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/index.html">Hypertension - not diabetic</a> for more information.</li><li><a class="topic-reference internal-reference" href="index.html#screening-for-type-2-diabetes-insulin-resistance">Screen</a> fortype 2 diabetes and insulin resistance,and manage appropriately. See the CKS topicon<a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a>forinformation on managing women with type 2 diabetes.</li><li>Check lipid levels. See the section on<a class="topic-reference external-reference" href="../../../lipid-modification-cvd-prevention/management/lipid-therapy-primary-prevention-of-cvd/index.html#interventions-tests-before-drug-treatment">Lipid measurement</a> in the CKS topic on<a class="topic-reference external-reference" href="../../../lipid-modification-cvd-prevention/index.html">Lipid modification - CVD prevention</a> for more information. Refer to a specialistif dyslipidaemia requires treatment.</li></ul></li><li><strong>If appropriate, calculate the woman's </strong><strong>10 year CVD riskusing the QRISK<sup></sup>2 assessment tool, and manage appropriately.</strong>See the CKS topic on<a class="topic-reference external-reference" href="../../../cvd-risk-assessment-management/index.html">CVD risk assessment and management</a>for more information. Note that:<ul><li>Conventional cardiovascular risk calculators have not been validated in women with polycystic ovary syndrome.</li><li>The QRISK<sup></sup>2 assessment tool is not suitable for:<ul><li>People who already have CVD.</li><li>People with type 1 diabetes.</li><li>People with chronic kidney disease (estimated glomerular filtration rate [eGFR]less than 60 mL/min/1.73 m<sup>2</sup>and/or albuminuria [a urinary albumin:creatinine ratiogreater than 3 mg/mmol]).</li><li>People with familial hypercholesterolaemia.</li><li>People aged 85 years or older.</li></ul></li></ul></li><li><strong>Offer all women with polycystic ovary syndrome (PCOS):</strong><ul><li>Regular monitoring for weight change and excess weight. Monitoring could be at each visit or at a minimum 612 monthly, with frequency, planned and agreed with the woman.</li><li>Annual bloodpressure checks (or more frequently based on global CVD risk).</li></ul></li></ul><!-- end field 5e3785f6-fe1c-4a5b-a812-6397a6f917fc --><!-- end item a6ad3721-6ec7-4d68-975d-d3e1e5d62139 --></div><section aria-labelledby="basis-for-recommendation-d22" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-d22">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d22a06bd-48e7-41cb-ae42-245b23a2cc14 --><!-- begin field 382d8a96-77bd-4e66-bdd4-6eec087b7775 --><p>These recommendations are based largely on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Long-term Consequences of Polycystic Ovary Syndrome</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>],<em>The polycystic ovary syndrome: a position statement from the European Society of Endocrinology </em>(ESE) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Conway, 2014</a>], and the<em>I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued bythe International Polycystic Ovary Syndrome<em> </em>(PCOS) Network [<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</p><h5>Assessing for (and managing) cardiovascular disease (CVD) risk</h5><ul><li>There is some evidence thatCVD risk factors areincreased in PCOS. See the section on<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">Complications</a> for more information.</li><li>CKS recommends that, in view of the possible increased risk of cardiovascular events, clinicians should give advice on measures to reduce cardiovascular risk.</li><li>The RCOG recommends thatbecause the lifetime risk for CVD is higher in women with PCOS, and is mostly preventable, all women with PCOS should be assessed for CVD risk by assessing individual CVD risk factors at baseline and managed accordingly[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>].</li><li>The International PCOS Network advises that women with PCOS should beassessed for cardiovascular risk factors and global CVD risk.If screening reveals CVD risk factors, including obesity, cigarette smoking, dyslipidemia, hypertension, impaired glucose tolerance, andlack of physical activity, the woman should be considered at increased risk of CVD[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</li></ul><h5>Referral if dyslipidaemia requires treatment</h5><ul><li>Although there is some evidence that statins improve hyperandrogenaemia and the metabolic profile in women with PCOS, they are not licensed for these indications. The RCOG advises that lipid-lowering treatment is not recommended routinely in women with PCOS and should only be prescribed by a specialist[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>].</li></ul><h5>Calculating cardiovascular risk score using the QRISK<sup></sup>2 tool</h5><ul><li>The QRISK<sup></sup>2 tool calculates a person'sestimated risk (not lifetime risk)of CVD over a 10 year period.See the CKS topic on<a class="topic-reference external-reference" href="../../../cvd-risk-assessment-management/index.html">CVD risk assessment and management</a>for more information.</li><li>The RCOG warns that while it seems prudent to assess the cardiovascular risk factors of a woman with PCOS, it should be noted that the conventional cardiovascular risk calculators have not been validated in this group of women[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>].</li></ul><h5>Offering all women with PCOS regular weight monitoring and annual blood pressure checks</h5><ul><li>This recommendation is based on expert opinion in the<em>I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</li></ul><!-- end field 382d8a96-77bd-4e66-bdd4-6eec087b7775 --><!-- end item d22a06bd-48e7-41cb-ae42-245b23a2cc14 --></div></section></section><section aria-labelledby="managing-clinical-features-of-polycystic-ovary-syndrome" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-clinical-features-of-polycystic-ovary-syndrome">How should I manage clinical features of polycystic ovary syndrome?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0278eca8-3034-4e08-8975-4d6f213be4d9 --><!-- begin field 366400ec-e2fb-489f-8dfb-59e5b1c4f293 --><ul><li><strong>Oligomenorrhoea or amenorrhoea</strong><ul><li>If the woman has prolonged amenorrhea (less than one period every three months), abnormal vaginal bleeding, or excess weight:<ul><li>Prescribe a cyclical progestogen (such as medroxyprogesterone 10mg daily for 14days) to inducea withdrawal bleed, <em>then </em></li><li>Refer for atransvaginal ultrasound to assessendometrial thickness.</li></ul></li><li>If endometrial thickening is present (greater than 10mm) or theendometrium has an unusual appearance:<ul><li>Refer for endometrial sampling to exclude endometrial hyperplasia or cancer.</li></ul></li><li>If the endometrium is of normal thickness and appearance, advise treatment to prevent endometrial hyperplasia.The choice of treatment depends on factors such as whether the woman wishes to have regular withdrawal bleeds (at leastevery 34months), whether she has acne or hirsutism, and whether there are any contraindications to treatment. Options include:<ul><li>A cyclical progestogen, such as medroxyprogesterone 10mg daily for 14days every 13months.</li><li>A low-dose combined oral contraceptive (COC). See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-combined-hormonal-methods/index.html">Contraception - combined hormonal methods</a>for prescribing information on COCs, including contraindications and cautions, choice, risksand adverse effects, and drug interactions.</li><li>The levonorgestrel-releasing intrauterine system (LNG-IUS). See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a>for prescribing information on the LNG-IUS, including contraindications, cautions, risks, and adverse effects.</li></ul></li><li>If the woman is unwilling to take cyclical hormone treatment or use the LNG-IUS, seek specialist advice or refer.Regular ultrasonography is likely to be required (for example every 612months) to assess endometrial thickness and morphology.</li><li>Encourage a healthy lifestyle to reduce the risk ofpossible long-term<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a> of polycystic ovary syndrome (PCOS).<ul><li>Advise women who are overweight or obese thatweight loss may result in menstrual regularity. See the CKS topic on<a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li></ul></li><li>Osteoporosis prophylaxis is <em>not</em> requiredfor women with PCOS who are amenorrhoeic, as they are not oestrogen deficient.</li></ul></li><li><strong>Acne</strong><ul><li>Encourage a healthy lifestyle to reduce the risk ofpossible long-term<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a> of PCOS.<ul><li>Advise women who are overweight or obese thatweight loss may reduce hyperandrogenism. See the CKS topic on<a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li></ul></li><li>Offer a COC as a first-line treatment, provided there are no contraindications. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-combined-hormonal-methods/index.html">Contraception - combined hormonal methods</a>for prescribing information on COCs, including contraindications and cautions, choice, risksand adverse effects, and drug interactions.</li><li>If needed, add a topical retoinoids, topical antibiotics, and/or oral antibiotics. See the CKStopic on<a class="topic-reference external-reference" href="../../../acne-vulgaris/index.html">Acne vulgaris</a>for more information on managing acne.</li></ul></li><li><strong>Hirsutism</strong><ul><li>Encourage a healthy lifestyle to reduce the risk ofpossible long-term<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a> of PCOS.<ul><li>Advise women who are overweight or obese thatweight loss may reduce hyperandrogenism. See the CKS topic on<a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li></ul></li><li>Discuss methodsof hair reduction and removal (such as shaving and waxing),as these will remain an important part of management. See the CKS topic on<a class="topic-reference external-reference" href="../../../hirsutism/index.html">Hirsutism</a>for more information.</li><li>Consider prescribing aCOC, provided there are no contraindications. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-combined-hormonal-methods/index.html">Contraception - combined hormonal methods</a>for prescribing information on COCs, including contraindications and cautions, choice, risksand adverse effects, and drug interactions.</li></ul></li><li><strong>Infertility</strong><ul><li>Carry out an assessmentto identify the possible causes of infertility, which might not be due to PCOS. See the CKS topic on<a class="topic-reference external-reference" href="../../../infertility/index.html">Infertility</a>for more information.</li><li>Encourage a healthy lifestyle to reduce the risk ofpossible long-term<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a> of PCOS.<ul><li>Advise women who are overweight or obese thatweight loss may improve the chance of pregnancy. See the CKS topic on<a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li><li>Advise women who smoke that smoking is likely to reduce their fertility and thatpassive smoking is likely to reduce their chances of conceiving. See the CKS topic on<a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a> for more information.</li></ul></li><li>Consider referral for fertility treatment.</li></ul></li></ul><!-- end field 366400ec-e2fb-489f-8dfb-59e5b1c4f293 --><!-- end item 0278eca8-3034-4e08-8975-4d6f213be4d9 --></div><section aria-labelledby="basis-for-recommendation-7db" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-7db">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7db916bd-f6eb-4a6c-9007-5f414e6bbdbe --><!-- begin field 0686eb41-2371-43d3-a231-7aee0d7d4124 --><p>These recommendations are based largely on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Long-term Consequences of Polycystic Ovary Syndrome</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>],<em>The polycystic ovary syndrome: a position statement from the European Society of Endocrinology </em>(ESE) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Conway, 2014</a>], and the<em>I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued bythe International Polycystic Ovary Syndrome<em> </em>(PCOS) Network [<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>].</p><h5>Inducing a withdrawal bleed</h5><ul><li>In women with PCOS, intervals between menstruation of more than 3 months (equivalent to fewer than four periods each year) may predispose to endometrial hyperplasia and later carcinoma. The RCOG states that [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2014</a>]:<ul><li>Itis good clinical practice to induce a withdrawal bleed at least every 34 months to reduce this risk. This can be done witha cyclical progestogens for at least 12 days, a combined oral contraceptive pill(COC),or alevonorgestrel-releasing intrauterine system. There is no evidence to suggest which is the most effective regimen.<ul><li>Medroxyprogesterone is indicatedfor endometrial protection from oestrogenic hormone replacement therapy as a 14-day course within each 28-day oestrogen hormone replacement therapy cycle [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 76, 2018</a>].</li></ul></li><li>Transvaginal ultrasound should be considered in the absence of withdrawal bleeds or abnormal uterine bleeding.</li><li>Athickened endometrium or an endometrial polyp should prompt consideration of endometrial biopsy and/or hysteroscopy (in PCOS, an endometrial thickness of less than 7 mm is unlikely to be hyperplasia).</li></ul></li><li>Accordingto the International PCOS Network[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>]:<ul><li>Routine ultrasound screening of endometrial thickness in PCOS is not recommended. However, health professionals require a low threshold for investigation of endometrial cancer in women with PCOS or a history of PCOS.</li><li>Investigation by transvaginal ultrasound and/or endometrial biopsy is recommended if there is persistent thickened endometrium and/or risk factors such as prolonged amenorrhea, abnormal vaginal bleeding, or excess weight.</li></ul></li></ul><h5>Managing women who are unwilling to take cyclical hormone treatment</h5><ul><li>These recommendations are based on expert opinion in a non-systematic review on PCOS and cancer[<a class="bibliography-reference internal-reference" href="../../references/index.html">Balen, 2001</a>].</li></ul><h5>Encouraging a healthy lifestyle</h5><ul><li>The ESE advises that [<a class="bibliography-reference internal-reference" href="../../references/index.html">Conway, 2014</a>]:<ul><li>Lifestyle modification, including diet and exercise, should be the first-line treatment in overweight and obese women with PCOS.</li><li>Regular exercisecombined with dietary advice aiming at sustained weight loss may ameliorate many aspects of PCOS in overweight/obese women.<ul><li>For example, weight reduction alone may result in spontaneous ovulation in these women, and in women who do not ovulate spontaneously following weight reduction and lifestyle modifications, the response to induction of ovulation is likely to be improved by these measures.</li></ul></li></ul></li><li>The International PCOS Network advises that[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>]:<ul><li>Healthy lifestyle behaviours (including healthy eating and regular physical activity) should be recommended in all those with PCOS to achieve and/or maintain a healthy weight and to optimize hormonal outcomes, general health, and quality of life.</li><li>Lifestyle intervention (preferably multicomponent, including diet, exercise, and behavioural strategies) should be recommended in all those with PCOS and excess weight, for reductions in weight, central obesity, and insulin resistance.</li></ul></li><li>Expert opinion in a British Fertility SocietyPolicy and Practice Guidelines is that a loss of more than 5% in body weight can be enough to restore fertility and improve metabolic markers[<a class="bibliography-reference internal-reference" href="../../references/index.html">Balen and Anderson, 2007</a>].</li></ul><h5>Choice of treatment </h5><ul><li>COCs are the mainstay of the pharmacological treatment of PCOS as they can be used to manage both menstrual disorders and androgen excess symptoms (such as acne and hirsutism). Progestogens, usually given cyclically, also have a role in the management of menstrual dysfunction [<a class="bibliography-reference internal-reference" href="../../references/index.html">Conway, 2014</a>].</li><li>The International PCOS Network advises that[<a class="bibliography-reference internal-reference" href="../../references/index.html">International PCOS Network, 2018</a>]:<ul><li>Provided there are no contraindications, the COCalone should be recommended in adult women with PCOS for management of hyperandrogenism and/or irregular menstrual cycles.</li><li>When deciding on a treatment, the womans personal characteristics, preferences, and values should be consideredas well as the benefits, adverse effects, and contraindications of the treatment.</li><li>The lowest effective oestrogen doses (such as 2030 micrograms of ethinyloestradiol or equivalent)and natural estrogen preparations should be considered whilst balancing efficacy, metabolic risk profile, adverse effects, cost, and availability.</li><li>The generally limited evidence on the effects of COCs in PCOS should be considered, with practice informed by general population guidelines.</li><li>PCOS specific risk factors, such as high body mass index, hyperlipidemia, and hypertension, need to be considered.</li></ul></li></ul><h5>Osteoporosis prophylaxis not required for women who are amenorrhoeic</h5><ul><li>Thisrecommendationis based on evidence fromcase-controlled studies[<a class="bibliography-reference internal-reference" href="../../references/index.html">Adami et al, 1998</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">To and Wong, 2005</a>]and on expert opinion in review articles on amenorrhoea[<a class="bibliography-reference internal-reference" href="../../references/index.html">Crosignani and Vegetti, 1996</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Baird, 1997</a>].<ul><li>Women with PCOS have some ovarian activity [<a class="bibliography-reference internal-reference" href="../../references/index.html">Crosignani and Vegetti, 1996</a>].Follicular development and oestrogen production continue but are arrested at some stage short of full maturation of an ovulatory follicle. Therefore, although these women are anovulatory, they do not show signs of oestrogen deficiency [<a class="bibliography-reference internal-reference" href="../../references/index.html">Baird, 1997</a>].<ul><li>A small case-controlled study of 45adolescent women with amenorrhoea or oligomenorrhoea (14 had polycystic ovaries) matched with 45women with regular menstruation found that, although overall the women with amenorrhoea or oligomenorrhoea had lower bone mineral density than those with regular menstruation, those with polycystic ovaries had a bone mineral density similar to that of the control group [<a class="bibliography-reference internal-reference" href="../../references/index.html">To and Wong, 2005</a>].</li><li>A subgroup of 51women with PCOS in a case-controlled study found that amenorrhoeic women with PCOS had only a marginal decrease in bone mass. Bone protection was thought to be due to adequate oestrogen production and overproduction of androgenic steroids [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adami et al, 1998</a>].</li></ul></li></ul></li></ul><!-- end field 0686eb41-2371-43d3-a231-7aee0d7d4124 --><!-- end item 7db916bd-f6eb-4a6c-9007-5f414e6bbdbe --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI"><!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/polycystic-ovary-syndrome/management/management-adults/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>